Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SOUTH KOREA

February 9, 2021

View Press Release Corporate presentation Contact us
Previous